{"success":true,"data":{"pressRelease":{"id":"149078","rtpr_id":"nGNE4ZgCZK-20260922","ticker":"DXSP","exchange":"","all_tickers":["DXSP"],"title":"REG-DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS FY 30 APRIL 2026 ","author":"Globe Newswire","published_at":"2026-09-22T06:00:00.429Z","article_body":"The information communicated within this announcement is deemed to constitute\ninside information as stipulated under the Market Abuse Regulation (EU) No\n596/2014 which is part of UK law by virtue of the European Union (Withdrawal)\nAct 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit)\nRegulations 2019. Upon publication of this announcement, this inside\ninformation is now considered to be in the public domain.\n\nDXS INTERNATIONAL PLC\n\n(AQSE: DXSP)\n\nANNUAL RESULTS \nfor the year ended 30 April 2026\n\nThe Board of DXS International plc (AQSE: DXSP)(“the Company”), the AQSE\nGrowth Market quoted healthcare information and digital clinical decision\nsupport systems provider, is pleased to announce its audited Final Results for\nthe year ended 30 April 2026.\n\nFinancial Highlights\n* Profit of £61,839 (2025: loss of £94,750).\n* Revenue decreased 5.2% to £3,289,052 (2025: £3,469,917).\n* Core recurring revenues remained resilient.\n* Period-end available cash of £393,258, comprising £83,610 cash at bank and\n£309,648 of unutilised debtor drawdowns.\n* Throughout this period  our strategy has remained to carefully manage costs\nand cashflow supported by the conversion of accrued management and shareholder\nloans converted into equity at prices significantly above prevailing market\nlevels.\nCommercial Update\n\nContinued investment in customer service and product development has resulted\nin all customers recently renewing their contracts for a further 18 months. We\nplan to implement a price increase between April and October 2027, reflecting\ninflation and expanded product capability. This has the potential to increase\nannual recurring revenue, although timing and value remain dependent on the\nnew NHS framework.\n\nBalance Sheet and Funding\n\nThe Group's balance sheet strengthened during the year through the conversion\nof accrued management and shareholder loans into equity at prices\nsignificantly above prevailing market levels, minimising dilution to existing\nshareholders.\n\nNHS Restructuring and Growth\n\nNHS restructuring, which has constrained growth in recent years, is beginning\nto create meaningful opportunities for DXS. As Integrated Care Boards (ICBs)\nconsolidate, our existing customer base is expected to encompass GP practices\nrepresenting approximately 6-8 million additional patients who do not\ncurrently use DXS SMART Referrals, creating a significant upsell opportunity.\n\nProduct Development\n\nSMART Referrals delivered a modest increase in revenue during the year, while\nour new NexGen SMART Referrals solution has received encouraging feedback from\npilot sites. Opportunities within hospital specialist units are also emerging,\nfocused on improving efficiency, reducing administrative workloads and\ndelivering healthcare savings.\n\nExpertCare, which is aligned with NHS medicines optimisation priorities, is\nshowing encouraging commercial interest, with further traction recorded during\nthe first quarter of 2027.\n\nPharmaceutical Advertising revenue remained broadly stable, with a modest\ndecline reflecting the timing of medicine information campaigns. It remains an\nimportant contributor to DXS revenue.\n\nOutlook\n\nThe NHS remains under significant pressure to improve efficiency and patient\noutcomes, with digital clinical solutions expected to play an increasingly\nimportant role in healthcare delivery. This aligns strongly with DXS' strategy\nand supports our continued investment in clinical technology, products and\nservices.\n\nDavid Immelman, Chief Executive of DXS, commented:\n“After several challenging years, we believe DXS is increasingly well\npositioned to benefit from the opportunities emerging across the NHS. Our\nfocus is firmly on converting these opportunities into sustainable recurring\nrevenue growth and improved profitability.\n\nThese efforts are underpinned by a talented, dynamic and increasingly\nexperienced team that understands the challenges facing our customers and how\nDXS can help address them. Alongside our focus on growth, we continue to\ninvest in developing the next generation of leaders within the business, with\nsenior members of the team actively mentoring and supporting their development\nto ensure continuity, strengthen our capabilities and position DXS for the\nfuture.”\n\nThe Directors of DXS International plc accept responsibility for this\nannouncement. This announcement contains information which, prior to its\ndisclosure, was inside information as stipulated under Regulation 11 of the\nMarket Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).\n\nContacts :\n\nDavid Immelman,\nCEO                                                                            \nTel: 01252 719800\nDXS International plc\nwww.dxs-systems.com\n\nAQSE Corporate Broker and Corporate Advisor\nHybridan\nLLP                                                                                           \nTel: 020 3764 2341\nClaire Louise Noyce\n\nNotes to Editors\n\nAbout DXS:\nDXS International is a UK-based digital health technology company that\ndevelops advanced clinical decision support and medicines optimisation\nsolutions widely used across the NHS, particularly in primary care. Its\nsoftware delivers evidence-based treatment guidelines and recommendations -\nsourced from Clinical Commissioning Groups and other trusted NHS authorities -\ndirectly to doctors, nurses, and pharmacists within their clinical workflow.\nBy enabling better-informed decisions at the point of care, DXS helps improve\npatient outcomes, enhance safety, and support the NHS in achieving its\nefficiency and cost-saving objectives\n\nThe following information is extracted from the DXS International plc audited\naccounts for the year ended 30 April 2026.\n\nCHAIRMAN’S REPORT\n\nThe year ended 30 April 2026 has been an important period for DXS. While NHS\nrestructuring has delayed purchasing decisions across the UK healthcare\nsector, this process is creating significant revenue opportunities, explained\nin more detail below, for DXS. While progress has taken longer than we had\nhoped, we are now beginning to see tangible developments in several of the\nareas in which we have invested heavily.\n\nThroughout this period of disruption, our strategy has remained consistent: to\ncontinue developing our technology, deliver a high-quality service to our\nexisting customers and carefully manage costs and cashflow. Against this\nbackground, the Group returned to profitability during the year.\n\nFinancial Highlights\n\nFor the year ended 30 April 2026, turnover was £3,289,052 (2025:\n£3,469,917), with a profit of £61,839 compared with a loss of £94,750 in\nthe prior year. This represents a reduction in turnover of approximately 5.2%,\nprimarily reflecting delayed customer purchasing decisions during NHS\nrestructuring, partially offset by a return to profitability following\ncontinued cost discipline. The Group had a reduced Loss from operations and\nthe profit after tax was mainly driven by the R&D Tax credit. Available cash\nat 30 April 2026 was £393,258 (£83,610 in cash at bank and £309,648\navailable from the factoring house). The Board continues to monitor the\nGroup's cash position and working capital requirements closely.\n\nCommercial Update\n\nOur continued investment in customer service and product development has\nresulted in all of our customers recently renewing their contracts for a\nfurther 18 months. We plan to implement a price increase between April and\nOctober 2027, reflecting the cost of inflation and expanded product\ncapability. If implemented as planned, we estimate this could significantly\nincrease our annual recurring revenue, although the timing and quantum remain\nsubject to a new NHS framework and are not guaranteed.\n\nBalance Sheet and Funding\n\nThe Group’s balance sheet also strengthened during the year, supported by\nthe conversion of accrued management and shareholder loans converted into\nequity at prices significantly above prevailing market levels; a structure\nwhich minimised dilution to existing shareholders. The Board is grateful for\nthis continued support and commitment, which reflects confidence in the\nGroup’s strategy, prospects and long-term potential.\n\nNHS Restructuring and Growth\n\nImportantly, the NHS restructuring that has constrained growth in recent years\nis now beginning to create meaningful opportunities for DXS. As ICB\n(Integrated Care Boards) consolidation, from 42 to 28, progresses towards its\ntarget, our existing customer base is expected to encompass GP practices\nrepresenting approximately 6–8 million additional patients that do not\ncurrently use our flagship product - DXS SMART Referrals. If only 50% of these\ncustomers elected to standardise to DXS SMART Referrals across their\npractices, this could generate more than £1 million of additional annual\nrecurring revenue. We currently expect the first such upsell opportunities to\nbegin from January 2027, although this depends on the pace of ICB\nconsolidation and on individual ICB customer decision-making, and may occur\nlater.\n\nProduct Development\n\nOur existing SMART Referral product showed encouraging results with a modest\nincrease in revenue for the year. ICB customer requested product enhancements\ncontinue to be delivered, and our new NexGen SMART Referral solution is\nreceiving enthusiastic feedback from pilot sites.\n\nWe are encouraged by progress in developing additional revenue streams. Our\nManaged Services offering provides clients with an ongoing liaison service\nwith hospital specialist units, helping to ensure that thousands of referral\nforms remain aligned with their specific requirements and supporting continued\nreductions in referral rejections.\n\nOur DXS Hubs, Metadata and SMART Forms services provide further opportunities\nto generate revenue from hospital specialist units and GP practices, while\nimproving efficiency, reducing administrative workloads and delivering savings\nin both healthcare resources and expenditure.\n\nFully aligned with NHS priorities for medicines optimisation, our evidenced\nExpertCare solution has also been impacted by NHS disruption. There are\nencouraging signs of commercial interest, and we anticipate further traction\nduring the first quarter of 2027.\n\nPharmaceutical Advertising revenue remained broadly stable, with a modest\ndecline largely reflecting changes in the timing of medicine information\ncampaigns by advertisers. This remains an important and consistent contributor\nto DXS’ recurring revenue.\n\nOn 18 December 2025, the Board reported that it had suffered a cyber security\nincident affecting its office servers, which was swiftly contained. DXS has\nremained vigilant by implementing additional monitoring and security measures.\n\nOutlook\n\nThe NHS continues to face significant pressure to improve healthcare\nefficiency and patient outcomes and is clear in its long-term strategy that\ndigital clinical solutions will play an increasingly important role in\nhealthcare delivery. This direction aligns strongly with DXS’ strategy and\nvalidates our continued investment in clinical technology, innovation and the\ndevelopment of our products and services.\n\nAfter several challenging years, we believe DXS is increasingly well\npositioned to benefit from the opportunities emerging across the NHS. Our\nfocus is now firmly on converting these opportunities into sustainable\nrecurring revenue growth and improved profitability.\n\nOn behalf of the Board, I would like to thank our shareholders, customers and\nemployees for their continued patience, commitment and support.\n\nBob Sutcliffe\n\nREPORT OF THE DIRECTORS\n\nThe directors present their annual report and the audited financial statements\nfor the year ended 30 April 2026. The Chairman’s statement which is included\nin this report includes a review of the achievements of the Company, the\ntrading performance, financial position, and trading prospects.\n\nDIRECTORS\n\nThe directors for the year were:\n* Bob Sutcliffe  –  Chairman\n* David Immelman  –  CEO\n* Steven Bauer  –  COO\nPRINCIPAL ACTIVITIES\n\nThe Group's principal activities during the period were the development and\ndistribution of clinical decision support to General Practitioners in the\nUnited Kingdom. The commercial side included the licensing of DXS to various\nICBs (Integrated Care Boards) and the sale of e-detailing opportunities to the\nPharmaceutical Industry.\n\nThe Group continues to invest in research and development both locally and\ninternationally and during this financial year has invested £713,472 (2025 -\n£705,292) excluding the 2026 cost of £595,000 for research and development\ntime spent by the South African subsidiary.\n\nDuring the period the Group has repaid £61,387 on bank and third-party loans.\nThe company borrowed a further loan of £100,000 with a balance of £89,964 at\nApril 2026.\n\nFINANCIAL INSTRUMENTS\n\nThe Directors believe that there is no material risk arising in respect of\ninterest rates on loans, credit, and liquidity.\n\nDIVIDEND\n\nThe Directors do not recommend a dividend.\n\nDIRECTORS’ RESPONSIBILITIES\n\nThe directors are responsible for preparing the annual report and financial\nstatements for each financial year. The directors have elected to prepare the\nfinancial statements in accordance with United Kingdom Generally Accepted\nAccounting Practice (United Kingdom Accounting Standards and applicable law).\nUnder company law the directors must not approve the financial statements\nunless they are satisfied that they give a true and fair view of the situation\nof the Group and Company and of the profit or loss of the Group for that\nperiod. In preparing these financial statements, the directors are required\nto:\n* Select suitable accounting policies and apply them consistently.\n* Make judgments and accounting estimates that are reasonable and prudent.\n* State whether UK accounting principles have been followed subject to any\nmaterial  and explained in the financial statements and,\n* Prepare the financial statements on the going concern basis unless it is\ninappropriate to presume that the Group and Company will continue in the\nbusiness.\nThe directors are responsible for keeping adequate accounting records that are\nsufficient to show and explain the Company's transactions and disclose with\nreasonable accuracy at any time the financial position of the Company and\nenable them to ensure that the financial statements comply with the Companies\nAct 2006. They are also responsible for safeguarding the assets of the Company\nand hence for taking reasonable steps for the prevention and detection of\nfraud and other irregularities.\n\nDIRECTORS’ RESPONSIBILITIES TO AUDITORS\n\nThe directors have taken all the necessary steps that they ought to have taken\nas directors to make themselves aware of all relevant audit information and to\nestablish that the Company's auditors are aware of that information.\n\nAs far as the directors are aware, there is no relevant audit information of\nwhich the Company’s auditor is unaware.\n\nApproved by the board and signed on its behalf by:\n\nDA Immelman\n\n10(th) September 2026\n\nSTRATEGIC REPORT\n\nSection 172 Report\n\nSection 172 of the Companies Act requires that a director of the Company is\nmanaging in the best interests of all stakeholders – Customers, Employees\nand Shareholders. \n\nIn the spirit of above, the Directors of DXS International plc, strive to\nmaintain a reputation for high but fair standards in the best interest of its\nstakeholders.\n\nOur primary focus is on our customers and here we regard our relationships and\nchannels of communications of paramount importance. We operate in a sensitive\nenvironment, healthcare, and as such ensure that we meet all the standards\nrequired by our customers, such as Information Governance and Clinical Safety.\nIn addition, we comply with ISO standards which assures an overarching good\ngovernance approach to all operations.\n\nThe Board is focused on delivering value for Shareholders underpinned by\nmotivated Employees delivering above average delivery of solutions and service\nto Customers. In achieving the foregoing, the Company focuses on continued\ninnovation via a policy of research and development funded through organic\ninvestment plus capital raises, as agreed at shareholder meetings.\n\nIn our communication to Shareholders the Board is clear in terms of its short,\nmedium, and long-term strategy and maintains an open-door approach to\nShareholders seeking additional clarity on any issue. The Board releases\nnotices on a regular basis informing Shareholders of developments in areas of\nbusiness progress, non-confidential strategic decisions, and any change to\ncompany policy. Risks and opportunities are set out in this strategic review.\n\nThe Group is small and while clear management structures are in place all\nemployees, if required, have direct access to the Executive Directors daily\nand, if necessary, to the Chairman. The Group retains HR services to ensure\nthe fair and equitable treatment of employees. The Company promotes a policy\nof promoting from within supported by training and mentorship. We encourage\ndiverse thinking and recognise strengths and contribution to the business.\n\nREVIEW OF THE GROUP’S BUSINESS\n\nThe Group profit for the year is £61,839 (2025: Loss of £94,750). The 2026\nprofit is primarily a result of prudent management of costs and an R&D tax\ncredit.\n\nAs an accredited NHS solutions provider, DXS has well-established business\ncontinuity and disaster recovery protocols in place.\n\nWe have continued the development of our new Next-Gen cloud-based system and\nare in the process of piloting this new version with good results. We are\nclose to completing the Lipids solution and hope to have this commercially\nviable by Jan 2027.\n\nAlthough the NHS remains notoriously slow in adopting new technology, our\nsustained efforts are seeing gained awareness of our new SMART referral and\nCVD prevention solution which we believe will begin generating revenue in late\n2026 or the first quarter in 2027.\n\nOur strategy remains aligned with both the new NHS Long Term Plan and\nopportunities abroad.\n\nPRINCIPAL RISKS AND UNCERTAINTIES \n\nThe going concern analysis was based on the premise that at worst we will\nretain existing revenue streams with growth coming only from our new Managed\nService offer and a long overdue price increase in October 2027. In an\neventuality of neither of these materialising, the company is prepared to\nimplement necessary cost cuts.\n\nThe principal risk to the Company in the UK is that the NHS dramatically\nchanges its plans or cuts its budgets. This seems unlikely, particularly with\nthe current NHS’ stated objective for clinicians to operate using digital\ntechnologies with which our new Next-Gen and ExpertCare solutions are aligned.\n\nFailure to achieve predicted quantities of DXS contracts, and slower\ndevelopment of additional revenue streams may result in revenues growing more\nslowly than anticipated. These may be mitigated due to existing DXS customers,\nwith some GP practices not yet having the DXS SMART Referral solution, wanting\nto standardise with a single referral solution across their complete patch.\n\nANALYSIS OF BUSINESS DURING YEAR ENDING 30 APRIL 2026\n\nNHS revenue was marginally up with overall revenue down by 5%, mainly due to a\nsmall drop in pharma revenue. Results improved with a profit of £61,839\n(2025: Loss of £94,750) with available cash of £393,258.\n\nFINANCIAL METRICS\n* Group Revenue of £3,289,052 (2025: £3,469,917) has decreased by 5%.\nDefinition: Total Group sales including distribution of clinical decision\nsupport to General Practitioners and the licensing of DXS to ICB’s which\nincreased. Group Revenue includes the sale of medicine education slots to the\npharmaceutical industry which marginally decreased. \n* Underlying Group profit after Tax was £61,839. The profit is mainly a\nresult of prudent management of costs and R&D tax credit.\n* Earnings Per Share 2026 0.1p, 2025 (0.1p). Definition: Earnings per share is\nthe underlying profit divided by the weighted average number of ordinary\nshares in issue.\n* ROE 2026 (17%) 2025 (26%). Definition: Return on Equity (ROE) is the ratio\nof net profit of a company to its shareholders funds. It measures the\nprofitability of a company by expressing its net profit as a percentage of its\nshareholders funds which include share capital, share premium, provision for\ncosts of share option awards and retained earnings.\nCORPORATE GOVERNANCE\n\nWe are committed to establish, maintain, and continually improve an Integrated\nManagement System (IMS) that conforms to relevant ISO requirements.\n\nTo achieve this objective, we commit to:\n* Continual improvement in our performance and services to our stakeholders.\n* Identify, assess, reduce, and eliminate hazards and risks pertaining to our\nbusiness.\n* Set risk-based objectives and targets to meet applicable statutory,\nbusiness, information security\nand service level obligations.\n* Comply with mutually agreed quality and service level requirements of our\ncustomers.\n* Develop our people and provide sufficient resources to meet our objectives\nand targets.\nWe communicate the IMS Policy to all personnel working for or on behalf of DXS\nto ensure that they are made aware of their individual IMS obligations.\n\nApproved by the board and signed on its behalf by:\n\nD Immelman\n\n10(th) September 2026\n\nFINANCIAL STATEMENTS\n\nINCOME STATEMENT\n\nYear ended 30 April 2026\n\n                                                2026 Continuing Operations    2025 Continuing Operations  \n                                                                                                          \n                                                £                             £                           \n Turnover                                       3,289,052                     3,469,917                   \n Cost of Sales                                  (428,209)                     (479,382)                   \n                                                _________                     _________                   \n Gross Profit                                   2,860,843                     2,990,535                   \n                                                                                                          \n Grant income                                   6,201                         132,993                     \n Administration costs                           (2,925,528)                   (3,251,011)                 \n                                                                                                          \n Depreciation and Amortisation                  -                             (1,038)                     \n Operating Loss                                 (58,484)                      (128,521)                   \n Sundry income                                  2,747                         1,898                       \n                                                _________                     _________                   \n                                                (55,737                       (126,623)                   \n Interest payable and similar expenses          (40,215)                      (48,525)                    \n                                                _________                     _________                   \n Loss on ordinary activities before taxation    (95,952)                      (175,148)                   \n Tax on loss on ordinary activities             157,791                       80,398                      \n                                                _________                     _________                   \n Profit / (Loss) for the year                   61,839                        (94,750)                    \n                                                =========                     =========                   \n Earnings per share                                                                                       \n * basic                                        0.1p                          (0.1p)                      \n * fully diluted                                0.1p                          (0.1p)                      \n                                                =========                     =========                   \n\nStatement of Other Comprehensive Income\n\n Year ended 30 April 2026                                 2026 £       2025 £     \n Profit / (Loss) for the year                             61,839       (94,750)   \n Other comprehensive income                               -            -          \n Tax on components of other comprehensive income          -            -          \n                                                          _________    _________  \n Total comprehensive income / (loss) for the year         61,839       (94,750)   \n                                                          =========    =========  \n\nStatement of Financial Position\n\nAs at 30 April 2026\n\n                                                 Group 2026   Group 2025   Company 2026  Company 2025  \n                                                 £            £            £             £             \n Fixed Assets                                                                                          \n Intangible Assets                               1,455,000    1,455,000    -             -             \n Tangible Assets                                 -            -            -             -             \n Investments                                     -            -            744,300       535,768       \n                                                 _________    _________    _________     _________     \n                                                 1,455,000    1,455,038    744,300       535,768       \n                                                 _________    _________    _________     _________     \n Current assets                                                                                        \n Debtors: amounts falling due within one year    524,897      486,556      20,887        44,507        \n Cash at bank and in hand                        83,610       428,957      13,072        16,810        \n                                                 _________    _________    _________     _________     \n                                                 608,507      915,513      33,959        61,317        \n Creditors: amounts falling due within one year  (553,967)    (908,986)    (126,984)     (143,674)     \n                                                 _________    _________    _________     _________     \n Net current assets / (liabilities)              54,540       6,527        (93,025)      (82,357)      \n                                                 _________    _________    _________     _________     \n                                                                                                       \n Total assets less current liabilities           1,509,540    1,461,527    651,275       453,411       \n                                                                                                       \n Creditors:                                                                                            \n Amounts falling due after more than one year    (243,303)    (285,353)    (164,981)     (95,939)      \n Deferred income                                 (779,943)    (814,542)    -             -             \n                                                 _________    _________    _________     _________     \n                                                 486,294      361,632      486,294       357,472       \n                                                 =========    =========    =========     =========     \n Capital and reserves                                                                                  \n Called up share capital                         227,857      211,273      227,857       211,273       \n Share premium                                   3,314,717    3,213,395    3,314,717     3,213,395     \n Share option reserve                            15,159       15,159       15,159        15,159        \n Retained earnings                               (3,071,439)  (3,078,195)  (3,071,439)   (3,082,355)   \n                                                 _________    _________    _________     _________     \n Shareholders’ funds                             486,294      361,632      486,294       357,472       \n                                                 =========    =========    =========     =========     \n                                                                                                       \n\nAs permitted by Section 408 of the Companies Act 2006, the Income Statement of\nthe parent company is not presented as part of these financial statements. The\nCompany made a profit of £65,999 (2025 – loss of (£98,910) for the year.\n\nThe financial statements were approved and authorized for issue by the Board\non 10th September 2026.\n\nSigned on behalf of the Board of directors\n\n D Immelman Director  R Sutcliffe Director  \n\nCompany Registration number :                 06311313\n\nStatement Of Changes in Equity\n\nYear ended 30 April 2026\nGroup\n\n                                         Called -up share capital  Share Premium  Share Option Reserve  Retained earnings  Total      \n                                         £                         £              £                     £                  £          \n At 30 April 2024                        211,273                   3,213,395      11,589                (2,988,871)        447,386    \n Transfer in respect of expired options  -                         -              (5,426)               5,426              -          \n Cost of share options awarded           -                         -              8,996                 -                  8,996      \n Loss for the year                       -                         -              -                     (94,750)           (94,750)   \n                                         _________                 _________      _________             _________          _________  \n At 30 April 2025                        211,273                   3,213,395      15,159                (3,078,195)        361,632    \n Share Issue                             16,584                    46,239         -                     -                  62,823     \n Transfer of reserves                    -                         55,083         -                     (55,083)           -          \n Profit for the year                     -                         -              -                     61,839             61,839     \n                                         _________                 _________      ________              _________          _________  \n At 30 April 2026                        227,857                   3,314,717      15,159                (3,071,439)        486,294    \n                                         =========                 =========      =========             =========          =========  \n\nTransfer from retained earnings to share premium was made in relation to the\ngain recognised from the waiver of loans to comply with the requirements of UK\ncompany law\n\nCompany\n\n                                             Called -up share capital  Share Premium  Share Option Reserve  Retained earnings  Total      \n                                             £                         £              £                     £                  £          \n At 30 April 2024                            211,273                   3,213,395      11,589                (2,988,871)        447,386    \n Transfer in respect of expired options      -                         -              (5,426)               5,426              -          \n Cost of share options and warrants awarded  -                         -              8,996                 -                  8,996      \n Loss for the year                           -                         -              -                     (98,910)           (98,910)   \n                                             _________                 _________      _________             _________          _________  \n At 30 April 2025                            211,273                   3,213,395      15,159                (3,082,355)        357,472    \n Share Issue                                 16,584                    46,239         -                     -                  -          \n Transfer of reserves                        -                         55,083         -                     (55,083)           -          \n Profit for the year                         -                         -              -                     65,999             65,999     \n                                             _________                 _________      ________              _________          _________  \n At 30 April 2026                            227,857                   3,314,717      15,159                (3,071,439)        486,294    \n                                             =========                 =========      =========             =========          =========  \n\nTransfer from retained earnings to share premium was made in relation to the\ngain recognised from the waiver of loans to comply with the requirements of UK\nlaw.\n\nSTATEMENT OF CASH FLOWS\n\nYear ended 30 April 2026\n\n                                                           Group 2026    Group 2025  \n                                                           £             £           \n Cash flow from operating activities                       (476,186)     247,071     \n Interest paid                                             (40,215)      (48,525)    \n Sundry income                                             2,747         1,898       \n Loss on Foreign Exchange                                  (13,097)      -           \n R&D tax credit received                                   142,791       195,798     \n                                                           _________     _________   \n Net cash flow from operating activities                   (383,960)     396,242     \n                                                           _________     _________   \n                                                                                     \n Financing Activities                                                                \n Repayment of long term loans                              (61,387)      (103,431)   \n Receipt of loan                                           100,000       -           \n Advances from directors and senior staff                  -             46,134      \n                                                           _________     _________   \n                                                           38,613        (57,297)    \n                                                           _________     _________   \n                                                                                     \n Net increase / (decrease) in cash and cash equivalents    (345,347)     338,945     \n Cash and Cash equivalents at 30 April 2025                428,957       90,012      \n                                                           _________     _________   \n Cash and Cash equivalents at 30 April 2026                83,610        428,957     \n                                                           =========     =========   \n Cash and Cash equivalents consists of:                                              \n Cash at bank and in hand                                  83,610        428,957     \n                                                           =========     =========   \n                                                                                     \n                                                                                     \n\n\n\n Net Debt Reconciliation  Current Debt  Non Current Debt  Cash       Total      \n                          £             £                 £          £          \n At 30 April 2024         (286,629)     (345,455)         90,012     (542,072)  \n Non - Cash Flow          -             60,102            -          60,102     \n Cash Flow                209,489       -                 338,945    548,434    \n                          ________      ________          ________   ________   \n At 30 April 2025         (77,140)      (285,353)         428,957    66,464     \n Non – cash flow          -             80,663            -          80,663     \n Cash Flow                              (38,613)          (345,347)  (383,960)  \n                          _________     _________         ________   _________  \n At 30 April 2026         (77,140)      (243,303)         83,610     (236,833)  \n                          =========     =========         =========  =========  \n\nNOTES TO THE FINANCIAL STATEMENTS\n\nYear ended 30 April 2026\n\nSummary of significant accounting policies\n\n(a)   General information and basis of preparation.\n\nDXS International PLC is a public company limited by shares incorporated in\nEngland and Wales. The address of the registered office is given in the\ncompany information on Page 1 of these financial statements.\n\nThe group's principal activities during the year were the development and\ndistribution of clinical decision support to General Practitioners, Nurses and\nRetail Pharmacies in the United Kingdom. The commercial side includes the\nlicensing of DXS products to various ICB's (Integrated Care Boards), the sale\nof e- detailing opportunities to the pharmaceutical industry, the UK Primary\nCare sector and the licencing of DXS technology to healthcare publishers.\n\nThe financial statements have been prepared in accordance with applicable\naccounting standards including Financial Reporting Standard 102, the Financial\nReporting Standard applicable in the UK and Republic of Ireland (FRS102) and\nthe Companies Act 2006.\n\nThe financial statements have been prepared on a going concern basis under the\nhistorical cost convention. The financial statements are prepared in sterling\nwhich is the functional currency of the company.\n\nIn the opinion of the Directors the group has sufficient funding to continue\nas a going concern for at least twelve months from the date of approval of the\nfinancial statements.\n\nThe significant accounting policies applied in the preparation of these\nfinancial statements are set out below. These policies have been consistently\napplied to all years presented unless otherwise stated.\n\n(b )   Intangible assets\n\nIntangible assets acquired separately from a business are capitalised at cost.\n\nResearch and development expenditure, other than specific identifiable\ndevelopment expenditure, is written off against profits in the year in which\nit is incurred.\n\nIdentifiable development expenditure is capitalised to the extent that the\ntechnical, commercial and financial feasibility can be demonstrated. Developed\nproducts are for use within the NHS and other medical institutions within both\nthe UK and internationally. The Group is already a supplier of services to the\nNHS.\n\nIntangible assets are amortised over a straight line basis over their useful\nlives. The useful lives of intangible assets are as follows:\n\n Intangible type          Useful life Reasons                                                            Reasons                                     \n Development expenditure  5 years from the date that the specific product is available for distribution  Period of time for benefit to be received.  \n\nProvision was made for impairment in 2024 as the recoverable amount of the\nasset was less than its carrying amount based on Directors judgement of the\nfuture revenue to be derived from each product. The Directors have considered\nthe current value of the asset and believe that no additional impairment\ncharge is required in the current year. (Note 1(m))\n\n(c ) Tangible fixed assets\n\nThe company capitalises items purchased as Tangible Fixed Assets which have a\ncost in excess of £550.\n\nTangible fixed assets are stated at cost less accumulated depreciation.\n\nDepreciation is provided on all tangible fixed assets at rates calculated to\nwrite off the cost , less estimated residual value, of each asset on a\nsystematic basis over its expected useful life as follows:\n\n Office equipment  3-4 years straight line.  \n\n(d)   Debtors and creditors receivable/ payable within one year\n\nDebtors and creditors with no stated interest rate and receivable or payable\nwithin one year are recorded at transaction price. Any losses arising from\nimpairment are recognised in the profit and loss account in other\nadministration expenses.\n\n(e)   Loans and borrowings\n\nLoans and borrowings are initially recognised at the transaction price\nincluding transaction costs. Subsequently they are measured at amortised cost\nusing an effective interest rate method. If an arrangement constitutes a\nfinance transaction it is measured at present value.\n\n(f)   Grants\n\nGovernment Grants, including non - monetary grants, shall not be recognised\nuntil there is reasonable assurance that :\n\n      (a)   the entity will comply with the conditions attached to\nthem; and\n\n      (b)   the grants will be received.\n\nAn entity shall recognise grants either based on the performance model or the\naccrual model. In the current year and prior year, the Grant has been\naccounted for on the accrual basis over the period in which the Group\nrecognised the related costs for which the grant is intended to compensate.\n\n(g)   Tax\n\nCurrent tax represents the amount of tax payable or receivable in respect of\nthe taxable profit for the current or past reporting periods. It is measured\nat the amount expected to be paid or recovered using the tax rates and laws\nthat have been enacted or substantively enacted by the reporting date.\n\n(h)   Turnover and other income\n\nTurnover is measured at the fair value of the consideration received or\nreceivable net of VAT and trade discounts. The policy adopted for the\nrecognition of turnover is as follows:\n\nSale of services and products\n\nTurnover is from the sale of products and services to the pharmaceutical\nindustry and the UK Primary Care sector and is recognised over the term of\nservice contract and is apportioned on a time basis representing the delivery\nof the service.\n\n(i)   Foreign currency\n\nForeign currency transactions are initially recognised by applying to the\nforeign currency amount the exchange rate between the functional currency and\nthe foreign currency at the date of the transaction.\n\nMonetary assets and liabilities denominated in a foreign currency at the\nbalance sheet date are translated using the closing rate.\n\nForeign exchange gains or losses are recognised in the Income Statement.\n\n(j)   Employee benefits\n\nWhen employees have rendered service to the company, short term employee\nbenefits to which the employees are entitled are recognised at the\nundiscounted amount expected to be paid in exchange for that service.\n\nThe company operates a defined contribution plan for the benefit of its\nemployees. Contributions are expensed as they become payable.\n\n(k)   Leases\n\nRentals payable under operating leases are charged to the income statement on\na straight line basis over the period of the lease.\n\n(l) Share option policy\n\nThe company recognised as an expense, the fair value of share options granted\nover their vesting period. The fair value is calculated by applying an option\npricing model.\n\n(m)   Key judgements and Key accounting estimates\n\nThe Key judgements or Key Accounting estimates with a material effect on the\ncarrying value of assets and liabilities are set out below -.\n\nGoing concern\n\nIn regards to the going concern of the group, the directors have considered\ncash flow forecasts for the period to April 2028 which include estimates to be\nearned from the new Next Gen SMART Referral solution which is anticipated to\nbe available for distribution during early 2027. Indications are that there\nwill be a significant demand for this product. Existing Point of Care\ncustomers have all renewed their continuity contracts until September 2027.\nAlso included within the Budget is a CPI price increase in April 2027 and a\nlong overdue product price increase in October 2027. The renewal of the NHS\ncentral funding framework which is expected to become effective in October\n2027 will enable existing NHS customers to procure the DXS SMART Referral\nsolution for practices that as yet do not have the referral solution\n\nThe Expertcare solution has been selected, provisionally, for inclusion in a\nmajor project by the NHS commencing in early 2027.\n\nThe successful evaluations of both the SMART Referral and Expertcare\nsolutions, both demonstrating strong ROI for the NHS, bode well for procuring\nnew sales for these solutions for 2027/28.\n\nThe Pharma division has found a number of new customers since the year end. A\nprice increase has also been implemented in the current year, which has been\naccepted by the current customers. The indication is that, with the benefit of\nthe new products, this division will be expanding in the forthcoming year.\n\nAlso included are costs which, if forecasted sales are slower than\nanticipated, can be reduced accordingly. While the forecasts include a number\nof positive assumptions relating to new customer acquisitions, anticipated\nsales from recently developed products, future contract opportunities, planned\nprice increases and potential cost mitigation actions, these represent\nmanagements best estimates rather than assumptions fundamental to the going\nconcern assessment. Sensitivity analysis performed demonstrates that, even if\nthese forecast benefits are excluded in full, the Group continues to maintain\nadequate liquidity and headroom throughout the forecast period and remains\nable to meet its liabilities as they fall due. Accordingly, the directors'\nconclusion that the Group is a going concern is not dependent upon the\nsuccessful delivery of these initiatives, and no material uncertainty relating\nto going concern has been identified.\n\nBased on the foregoing, the directors consider it appropriate to adopt the\ngoing concern basis of accounting and are satisfied that there is no material\nuncertainty.\n\nResearch and Development Tax credit\n\nThe Research and Development tax credit received from HMRC is not a Government\ngrant but a recognition of the costs incurred in respect of the company's\nresearch and development and is received through an adjustment to the taxable\nincome of the company.\n\nImpairment\n\nAs per the NHS mandate requiring NHS accredited suppliers to continue a\nprocess of innovation, the Group has invested heavily into developing new\ninnovative solutions to meet the NHS unmet needs. However, while there is no\ndoubt as to the potential benefits to be realised for the NHS, the slow pace\nat which the NHS has been, and continues to operate is frustrating.\n\nThe Government did not provide the anticipated funding to the NHS during\n2024/25 or 2025/26 . Funds were not available for purchase of new products by\nthe NHS, The Government has indicated that significant funds for new products\nwill be made available in the fiscal year commencing October 2027.\n\nThe slow pace at which the NHS has operated over the last few years has been\nextremely frustrating. The main reasons are the reduction in the ICBs causing\nstaff concerns for potential staff redundancies, the delayed appointment of\nsenior staff in the new combined organisations and the appointment of 2\nSecretaries for State since the last General election.\n\nThere are indications that the NHS is slowly improving its delivery time for\npatients and is taking steps to resolve the current issues within product\nprocurement.\n\nThe company's products are in line with the those included in the NHS new 10\nyear plan. The new products are undergoing pilot testings. The initial reports\nindicate that only minor amendments to the products are required. And there\nappears a demand for these products when they have completed all the tests.\nThere are also studies showing a significant cash saving to the NHS by the\nutilisation of these products\n\nGiven all these factors, the Directors believe that there are no impairment\nindicators and no further impairment provision is required in the current\nyear.\n\n(n)   Reduced disclosure\n\nDXS International PLC meets the definition of a qualifying entity under FRS\n102 paragraph 1.12(b) and has therefore taken advantage of the disclosure\nexemption in relation to the parent cash flow statement.\n\nAttachment\n*     DXS - Announcement Full Year 2026 - 22 September 2026\n(https://ml-eu.globenewswire.com/Resource/Download/c6e565f3-08b7-49d8-885c-22f0f1fc9d44)","article_body_html":"","raw_payload":{"data":{"id":"nGNE4ZgCZK-20260922","title":"REG-DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS FY 30 APRIL 2026 ","author":"Globe Newswire","ticker":"DXSP","created":"2026-09-22T06:00:00.429Z","tickers":["DXSP"],"exchange":"","article_body":"The information communicated within this announcement is deemed to constitute\ninside information as stipulated under the Market Abuse Regulation (EU) No\n596/2014 which is part of UK law by virtue of the European Union (Withdrawal)\nAct 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit)\nRegulations 2019. Upon publication of this announcement, this inside\ninformation is now considered to be in the public domain.\n\nDXS INTERNATIONAL PLC\n\n(AQSE: DXSP)\n\nANNUAL RESULTS \nfor the year ended 30 April 2026\n\nThe Board of DXS International plc (AQSE: DXSP)(“the Company”), the AQSE\nGrowth Market quoted healthcare information and digital clinical decision\nsupport systems provider, is pleased to announce its audited Final Results for\nthe year ended 30 April 2026.\n\nFinancial Highlights\n* Profit of £61,839 (2025: loss of £94,750).\n* Revenue decreased 5.2% to £3,289,052 (2025: £3,469,917).\n* Core recurring revenues remained resilient.\n* Period-end available cash of £393,258, comprising £83,610 cash at bank and\n£309,648 of unutilised debtor drawdowns.\n* Throughout this period  our strategy has remained to carefully manage costs\nand cashflow supported by the conversion of accrued management and shareholder\nloans converted into equity at prices significantly above prevailing market\nlevels.\nCommercial Update\n\nContinued investment in customer service and product development has resulted\nin all customers recently renewing their contracts for a further 18 months. We\nplan to implement a price increase between April and October 2027, reflecting\ninflation and expanded product capability. This has the potential to increase\nannual recurring revenue, although timing and value remain dependent on the\nnew NHS framework.\n\nBalance Sheet and Funding\n\nThe Group's balance sheet strengthened during the year through the conversion\nof accrued management and shareholder loans into equity at prices\nsignificantly above prevailing market levels, minimising dilution to existing\nshareholders.\n\nNHS Restructuring and Growth\n\nNHS restructuring, which has constrained growth in recent years, is beginning\nto create meaningful opportunities for DXS. As Integrated Care Boards (ICBs)\nconsolidate, our existing customer base is expected to encompass GP practices\nrepresenting approximately 6-8 million additional patients who do not\ncurrently use DXS SMART Referrals, creating a significant upsell opportunity.\n\nProduct Development\n\nSMART Referrals delivered a modest increase in revenue during the year, while\nour new NexGen SMART Referrals solution has received encouraging feedback from\npilot sites. Opportunities within hospital specialist units are also emerging,\nfocused on improving efficiency, reducing administrative workloads and\ndelivering healthcare savings.\n\nExpertCare, which is aligned with NHS medicines optimisation priorities, is\nshowing encouraging commercial interest, with further traction recorded during\nthe first quarter of 2027.\n\nPharmaceutical Advertising revenue remained broadly stable, with a modest\ndecline reflecting the timing of medicine information campaigns. It remains an\nimportant contributor to DXS revenue.\n\nOutlook\n\nThe NHS remains under significant pressure to improve efficiency and patient\noutcomes, with digital clinical solutions expected to play an increasingly\nimportant role in healthcare delivery. This aligns strongly with DXS' strategy\nand supports our continued investment in clinical technology, products and\nservices.\n\nDavid Immelman, Chief Executive of DXS, commented:\n“After several challenging years, we believe DXS is increasingly well\npositioned to benefit from the opportunities emerging across the NHS. Our\nfocus is firmly on converting these opportunities into sustainable recurring\nrevenue growth and improved profitability.\n\nThese efforts are underpinned by a talented, dynamic and increasingly\nexperienced team that understands the challenges facing our customers and how\nDXS can help address them. Alongside our focus on growth, we continue to\ninvest in developing the next generation of leaders within the business, with\nsenior members of the team actively mentoring and supporting their development\nto ensure continuity, strengthen our capabilities and position DXS for the\nfuture.”\n\nThe Directors of DXS International plc accept responsibility for this\nannouncement. This announcement contains information which, prior to its\ndisclosure, was inside information as stipulated under Regulation 11 of the\nMarket Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).\n\nContacts :\n\nDavid Immelman,\nCEO                                                                            \nTel: 01252 719800\nDXS International plc\nwww.dxs-systems.com\n\nAQSE Corporate Broker and Corporate Advisor\nHybridan\nLLP                                                                                           \nTel: 020 3764 2341\nClaire Louise Noyce\n\nNotes to Editors\n\nAbout DXS:\nDXS International is a UK-based digital health technology company that\ndevelops advanced clinical decision support and medicines optimisation\nsolutions widely used across the NHS, particularly in primary care. Its\nsoftware delivers evidence-based treatment guidelines and recommendations -\nsourced from Clinical Commissioning Groups and other trusted NHS authorities -\ndirectly to doctors, nurses, and pharmacists within their clinical workflow.\nBy enabling better-informed decisions at the point of care, DXS helps improve\npatient outcomes, enhance safety, and support the NHS in achieving its\nefficiency and cost-saving objectives\n\nThe following information is extracted from the DXS International plc audited\naccounts for the year ended 30 April 2026.\n\nCHAIRMAN’S REPORT\n\nThe year ended 30 April 2026 has been an important period for DXS. While NHS\nrestructuring has delayed purchasing decisions across the UK healthcare\nsector, this process is creating significant revenue opportunities, explained\nin more detail below, for DXS. While progress has taken longer than we had\nhoped, we are now beginning to see tangible developments in several of the\nareas in which we have invested heavily.\n\nThroughout this period of disruption, our strategy has remained consistent: to\ncontinue developing our technology, deliver a high-quality service to our\nexisting customers and carefully manage costs and cashflow. Against this\nbackground, the Group returned to profitability during the year.\n\nFinancial Highlights\n\nFor the year ended 30 April 2026, turnover was £3,289,052 (2025:\n£3,469,917), with a profit of £61,839 compared with a loss of £94,750 in\nthe prior year. This represents a reduction in turnover of approximately 5.2%,\nprimarily reflecting delayed customer purchasing decisions during NHS\nrestructuring, partially offset by a return to profitability following\ncontinued cost discipline. The Group had a reduced Loss from operations and\nthe profit after tax was mainly driven by the R&D Tax credit. Available cash\nat 30 April 2026 was £393,258 (£83,610 in cash at bank and £309,648\navailable from the factoring house). The Board continues to monitor the\nGroup's cash position and working capital requirements closely.\n\nCommercial Update\n\nOur continued investment in customer service and product development has\nresulted in all of our customers recently renewing their contracts for a\nfurther 18 months. We plan to implement a price increase between April and\nOctober 2027, reflecting the cost of inflation and expanded product\ncapability. If implemented as planned, we estimate this could significantly\nincrease our annual recurring revenue, although the timing and quantum remain\nsubject to a new NHS framework and are not guaranteed.\n\nBalance Sheet and Funding\n\nThe Group’s balance sheet also strengthened during the year, supported by\nthe conversion of accrued management and shareholder loans converted into\nequity at prices significantly above prevailing market levels; a structure\nwhich minimised dilution to existing shareholders. The Board is grateful for\nthis continued support and commitment, which reflects confidence in the\nGroup’s strategy, prospects and long-term potential.\n\nNHS Restructuring and Growth\n\nImportantly, the NHS restructuring that has constrained growth in recent years\nis now beginning to create meaningful opportunities for DXS. As ICB\n(Integrated Care Boards) consolidation, from 42 to 28, progresses towards its\ntarget, our existing customer base is expected to encompass GP practices\nrepresenting approximately 6–8 million additional patients that do not\ncurrently use our flagship product - DXS SMART Referrals. If only 50% of these\ncustomers elected to standardise to DXS SMART Referrals across their\npractices, this could generate more than £1 million of additional annual\nrecurring revenue. We currently expect the first such upsell opportunities to\nbegin from January 2027, although this depends on the pace of ICB\nconsolidation and on individual ICB customer decision-making, and may occur\nlater.\n\nProduct Development\n\nOur existing SMART Referral product showed encouraging results with a modest\nincrease in revenue for the year. ICB customer requested product enhancements\ncontinue to be delivered, and our new NexGen SMART Referral solution is\nreceiving enthusiastic feedback from pilot sites.\n\nWe are encouraged by progress in developing additional revenue streams. Our\nManaged Services offering provides clients with an ongoing liaison service\nwith hospital specialist units, helping to ensure that thousands of referral\nforms remain aligned with their specific requirements and supporting continued\nreductions in referral rejections.\n\nOur DXS Hubs, Metadata and SMART Forms services provide further opportunities\nto generate revenue from hospital specialist units and GP practices, while\nimproving efficiency, reducing administrative workloads and delivering savings\nin both healthcare resources and expenditure.\n\nFully aligned with NHS priorities for medicines optimisation, our evidenced\nExpertCare solution has also been impacted by NHS disruption. There are\nencouraging signs of commercial interest, and we anticipate further traction\nduring the first quarter of 2027.\n\nPharmaceutical Advertising revenue remained broadly stable, with a modest\ndecline largely reflecting changes in the timing of medicine information\ncampaigns by advertisers. This remains an important and consistent contributor\nto DXS’ recurring revenue.\n\nOn 18 December 2025, the Board reported that it had suffered a cyber security\nincident affecting its office servers, which was swiftly contained. DXS has\nremained vigilant by implementing additional monitoring and security measures.\n\nOutlook\n\nThe NHS continues to face significant pressure to improve healthcare\nefficiency and patient outcomes and is clear in its long-term strategy that\ndigital clinical solutions will play an increasingly important role in\nhealthcare delivery. This direction aligns strongly with DXS’ strategy and\nvalidates our continued investment in clinical technology, innovation and the\ndevelopment of our products and services.\n\nAfter several challenging years, we believe DXS is increasingly well\npositioned to benefit from the opportunities emerging across the NHS. Our\nfocus is now firmly on converting these opportunities into sustainable\nrecurring revenue growth and improved profitability.\n\nOn behalf of the Board, I would like to thank our shareholders, customers and\nemployees for their continued patience, commitment and support.\n\nBob Sutcliffe\n\nREPORT OF THE DIRECTORS\n\nThe directors present their annual report and the audited financial statements\nfor the year ended 30 April 2026. The Chairman’s statement which is included\nin this report includes a review of the achievements of the Company, the\ntrading performance, financial position, and trading prospects.\n\nDIRECTORS\n\nThe directors for the year were:\n* Bob Sutcliffe  –  Chairman\n* David Immelman  –  CEO\n* Steven Bauer  –  COO\nPRINCIPAL ACTIVITIES\n\nThe Group's principal activities during the period were the development and\ndistribution of clinical decision support to General Practitioners in the\nUnited Kingdom. The commercial side included the licensing of DXS to various\nICBs (Integrated Care Boards) and the sale of e-detailing opportunities to the\nPharmaceutical Industry.\n\nThe Group continues to invest in research and development both locally and\ninternationally and during this financial year has invested £713,472 (2025 -\n£705,292) excluding the 2026 cost of £595,000 for research and development\ntime spent by the South African subsidiary.\n\nDuring the period the Group has repaid £61,387 on bank and third-party loans.\nThe company borrowed a further loan of £100,000 with a balance of £89,964 at\nApril 2026.\n\nFINANCIAL INSTRUMENTS\n\nThe Directors believe that there is no material risk arising in respect of\ninterest rates on loans, credit, and liquidity.\n\nDIVIDEND\n\nThe Directors do not recommend a dividend.\n\nDIRECTORS’ RESPONSIBILITIES\n\nThe directors are responsible for preparing the annual report and financial\nstatements for each financial year. The directors have elected to prepare the\nfinancial statements in accordance with United Kingdom Generally Accepted\nAccounting Practice (United Kingdom Accounting Standards and applicable law).\nUnder company law the directors must not approve the financial statements\nunless they are satisfied that they give a true and fair view of the situation\nof the Group and Company and of the profit or loss of the Group for that\nperiod. In preparing these financial statements, the directors are required\nto:\n* Select suitable accounting policies and apply them consistently.\n* Make judgments and accounting estimates that are reasonable and prudent.\n* State whether UK accounting principles have been followed subject to any\nmaterial  and explained in the financial statements and,\n* Prepare the financial statements on the going concern basis unless it is\ninappropriate to presume that the Group and Company will continue in the\nbusiness.\nThe directors are responsible for keeping adequate accounting records that are\nsufficient to show and explain the Company's transactions and disclose with\nreasonable accuracy at any time the financial position of the Company and\nenable them to ensure that the financial statements comply with the Companies\nAct 2006. They are also responsible for safeguarding the assets of the Company\nand hence for taking reasonable steps for the prevention and detection of\nfraud and other irregularities.\n\nDIRECTORS’ RESPONSIBILITIES TO AUDITORS\n\nThe directors have taken all the necessary steps that they ought to have taken\nas directors to make themselves aware of all relevant audit information and to\nestablish that the Company's auditors are aware of that information.\n\nAs far as the directors are aware, there is no relevant audit information of\nwhich the Company’s auditor is unaware.\n\nApproved by the board and signed on its behalf by:\n\nDA Immelman\n\n10(th) September 2026\n\nSTRATEGIC REPORT\n\nSection 172 Report\n\nSection 172 of the Companies Act requires that a director of the Company is\nmanaging in the best interests of all stakeholders – Customers, Employees\nand Shareholders. \n\nIn the spirit of above, the Directors of DXS International plc, strive to\nmaintain a reputation for high but fair standards in the best interest of its\nstakeholders.\n\nOur primary focus is on our customers and here we regard our relationships and\nchannels of communications of paramount importance. We operate in a sensitive\nenvironment, healthcare, and as such ensure that we meet all the standards\nrequired by our customers, such as Information Governance and Clinical Safety.\nIn addition, we comply with ISO standards which assures an overarching good\ngovernance approach to all operations.\n\nThe Board is focused on delivering value for Shareholders underpinned by\nmotivated Employees delivering above average delivery of solutions and service\nto Customers. In achieving the foregoing, the Company focuses on continued\ninnovation via a policy of research and development funded through organic\ninvestment plus capital raises, as agreed at shareholder meetings.\n\nIn our communication to Shareholders the Board is clear in terms of its short,\nmedium, and long-term strategy and maintains an open-door approach to\nShareholders seeking additional clarity on any issue. The Board releases\nnotices on a regular basis informing Shareholders of developments in areas of\nbusiness progress, non-confidential strategic decisions, and any change to\ncompany policy. Risks and opportunities are set out in this strategic review.\n\nThe Group is small and while clear management structures are in place all\nemployees, if required, have direct access to the Executive Directors daily\nand, if necessary, to the Chairman. The Group retains HR services to ensure\nthe fair and equitable treatment of employees. The Company promotes a policy\nof promoting from within supported by training and mentorship. We encourage\ndiverse thinking and recognise strengths and contribution to the business.\n\nREVIEW OF THE GROUP’S BUSINESS\n\nThe Group profit for the year is £61,839 (2025: Loss of £94,750). The 2026\nprofit is primarily a result of prudent management of costs and an R&D tax\ncredit.\n\nAs an accredited NHS solutions provider, DXS has well-established business\ncontinuity and disaster recovery protocols in place.\n\nWe have continued the development of our new Next-Gen cloud-based system and\nare in the process of piloting this new version with good results. We are\nclose to completing the Lipids solution and hope to have this commercially\nviable by Jan 2027.\n\nAlthough the NHS remains notoriously slow in adopting new technology, our\nsustained efforts are seeing gained awareness of our new SMART referral and\nCVD prevention solution which we believe will begin generating revenue in late\n2026 or the first quarter in 2027.\n\nOur strategy remains aligned with both the new NHS Long Term Plan and\nopportunities abroad.\n\nPRINCIPAL RISKS AND UNCERTAINTIES \n\nThe going concern analysis was based on the premise that at worst we will\nretain existing revenue streams with growth coming only from our new Managed\nService offer and a long overdue price increase in October 2027. In an\neventuality of neither of these materialising, the company is prepared to\nimplement necessary cost cuts.\n\nThe principal risk to the Company in the UK is that the NHS dramatically\nchanges its plans or cuts its budgets. This seems unlikely, particularly with\nthe current NHS’ stated objective for clinicians to operate using digital\ntechnologies with which our new Next-Gen and ExpertCare solutions are aligned.\n\nFailure to achieve predicted quantities of DXS contracts, and slower\ndevelopment of additional revenue streams may result in revenues growing more\nslowly than anticipated. These may be mitigated due to existing DXS customers,\nwith some GP practices not yet having the DXS SMART Referral solution, wanting\nto standardise with a single referral solution across their complete patch.\n\nANALYSIS OF BUSINESS DURING YEAR ENDING 30 APRIL 2026\n\nNHS revenue was marginally up with overall revenue down by 5%, mainly due to a\nsmall drop in pharma revenue. Results improved with a profit of £61,839\n(2025: Loss of £94,750) with available cash of £393,258.\n\nFINANCIAL METRICS\n* Group Revenue of £3,289,052 (2025: £3,469,917) has decreased by 5%.\nDefinition: Total Group sales including distribution of clinical decision\nsupport to General Practitioners and the licensing of DXS to ICB’s which\nincreased. Group Revenue includes the sale of medicine education slots to the\npharmaceutical industry which marginally decreased. \n* Underlying Group profit after Tax was £61,839. The profit is mainly a\nresult of prudent management of costs and R&D tax credit.\n* Earnings Per Share 2026 0.1p, 2025 (0.1p). Definition: Earnings per share is\nthe underlying profit divided by the weighted average number of ordinary\nshares in issue.\n* ROE 2026 (17%) 2025 (26%). Definition: Return on Equity (ROE) is the ratio\nof net profit of a company to its shareholders funds. It measures the\nprofitability of a company by expressing its net profit as a percentage of its\nshareholders funds which include share capital, share premium, provision for\ncosts of share option awards and retained earnings.\nCORPORATE GOVERNANCE\n\nWe are committed to establish, maintain, and continually improve an Integrated\nManagement System (IMS) that conforms to relevant ISO requirements.\n\nTo achieve this objective, we commit to:\n* Continual improvement in our performance and services to our stakeholders.\n* Identify, assess, reduce, and eliminate hazards and risks pertaining to our\nbusiness.\n* Set risk-based objectives and targets to meet applicable statutory,\nbusiness, information security\nand service level obligations.\n* Comply with mutually agreed quality and service level requirements of our\ncustomers.\n* Develop our people and provide sufficient resources to meet our objectives\nand targets.\nWe communicate the IMS Policy to all personnel working for or on behalf of DXS\nto ensure that they are made aware of their individual IMS obligations.\n\nApproved by the board and signed on its behalf by:\n\nD Immelman\n\n10(th) September 2026\n\nFINANCIAL STATEMENTS\n\nINCOME STATEMENT\n\nYear ended 30 April 2026\n\n                                                2026 Continuing Operations    2025 Continuing Operations  \n                                                                                                          \n                                                £                             £                           \n Turnover                                       3,289,052                     3,469,917                   \n Cost of Sales                                  (428,209)                     (479,382)                   \n                                                _________                     _________                   \n Gross Profit                                   2,860,843                     2,990,535                   \n                                                                                                          \n Grant income                                   6,201                         132,993                     \n Administration costs                           (2,925,528)                   (3,251,011)                 \n                                                                                                          \n Depreciation and Amortisation                  -                             (1,038)                     \n Operating Loss                                 (58,484)                      (128,521)                   \n Sundry income                                  2,747                         1,898                       \n                                                _________                     _________                   \n                                                (55,737                       (126,623)                   \n Interest payable and similar expenses          (40,215)                      (48,525)                    \n                                                _________                     _________                   \n Loss on ordinary activities before taxation    (95,952)                      (175,148)                   \n Tax on loss on ordinary activities             157,791                       80,398                      \n                                                _________                     _________                   \n Profit / (Loss) for the year                   61,839                        (94,750)                    \n                                                =========                     =========                   \n Earnings per share                                                                                       \n * basic                                        0.1p                          (0.1p)                      \n * fully diluted                                0.1p                          (0.1p)                      \n                                                =========                     =========                   \n\nStatement of Other Comprehensive Income\n\n Year ended 30 April 2026                                 2026 £       2025 £     \n Profit / (Loss) for the year                             61,839       (94,750)   \n Other comprehensive income                               -            -          \n Tax on components of other comprehensive income          -            -          \n                                                          _________    _________  \n Total comprehensive income / (loss) for the year         61,839       (94,750)   \n                                                          =========    =========  \n\nStatement of Financial Position\n\nAs at 30 April 2026\n\n                                                 Group 2026   Group 2025   Company 2026  Company 2025  \n                                                 £            £            £             £             \n Fixed Assets                                                                                          \n Intangible Assets                               1,455,000    1,455,000    -             -             \n Tangible Assets                                 -            -            -             -             \n Investments                                     -            -            744,300       535,768       \n                                                 _________    _________    _________     _________     \n                                                 1,455,000    1,455,038    744,300       535,768       \n                                                 _________    _________    _________     _________     \n Current assets                                                                                        \n Debtors: amounts falling due within one year    524,897      486,556      20,887        44,507        \n Cash at bank and in hand                        83,610       428,957      13,072        16,810        \n                                                 _________    _________    _________     _________     \n                                                 608,507      915,513      33,959        61,317        \n Creditors: amounts falling due within one year  (553,967)    (908,986)    (126,984)     (143,674)     \n                                                 _________    _________    _________     _________     \n Net current assets / (liabilities)              54,540       6,527        (93,025)      (82,357)      \n                                                 _________    _________    _________     _________     \n                                                                                                       \n Total assets less current liabilities           1,509,540    1,461,527    651,275       453,411       \n                                                                                                       \n Creditors:                                                                                            \n Amounts falling due after more than one year    (243,303)    (285,353)    (164,981)     (95,939)      \n Deferred income                                 (779,943)    (814,542)    -             -             \n                                                 _________    _________    _________     _________     \n                                                 486,294      361,632      486,294       357,472       \n                                                 =========    =========    =========     =========     \n Capital and reserves                                                                                  \n Called up share capital                         227,857      211,273      227,857       211,273       \n Share premium                                   3,314,717    3,213,395    3,314,717     3,213,395     \n Share option reserve                            15,159       15,159       15,159        15,159        \n Retained earnings                               (3,071,439)  (3,078,195)  (3,071,439)   (3,082,355)   \n                                                 _________    _________    _________     _________     \n Shareholders’ funds                             486,294      361,632      486,294       357,472       \n                                                 =========    =========    =========     =========     \n                                                                                                       \n\nAs permitted by Section 408 of the Companies Act 2006, the Income Statement of\nthe parent company is not presented as part of these financial statements. The\nCompany made a profit of £65,999 (2025 – loss of (£98,910) for the year.\n\nThe financial statements were approved and authorized for issue by the Board\non 10th September 2026.\n\nSigned on behalf of the Board of directors\n\n D Immelman Director  R Sutcliffe Director  \n\nCompany Registration number :                 06311313\n\nStatement Of Changes in Equity\n\nYear ended 30 April 2026\nGroup\n\n                                         Called -up share capital  Share Premium  Share Option Reserve  Retained earnings  Total      \n                                         £                         £              £                     £                  £          \n At 30 April 2024                        211,273                   3,213,395      11,589                (2,988,871)        447,386    \n Transfer in respect of expired options  -                         -              (5,426)               5,426              -          \n Cost of share options awarded           -                         -              8,996                 -                  8,996      \n Loss for the year                       -                         -              -                     (94,750)           (94,750)   \n                                         _________                 _________      _________             _________          _________  \n At 30 April 2025                        211,273                   3,213,395      15,159                (3,078,195)        361,632    \n Share Issue                             16,584                    46,239         -                     -                  62,823     \n Transfer of reserves                    -                         55,083         -                     (55,083)           -          \n Profit for the year                     -                         -              -                     61,839             61,839     \n                                         _________                 _________      ________              _________          _________  \n At 30 April 2026                        227,857                   3,314,717      15,159                (3,071,439)        486,294    \n                                         =========                 =========      =========             =========          =========  \n\nTransfer from retained earnings to share premium was made in relation to the\ngain recognised from the waiver of loans to comply with the requirements of UK\ncompany law\n\nCompany\n\n                                             Called -up share capital  Share Premium  Share Option Reserve  Retained earnings  Total      \n                                             £                         £              £                     £                  £          \n At 30 April 2024                            211,273                   3,213,395      11,589                (2,988,871)        447,386    \n Transfer in respect of expired options      -                         -              (5,426)               5,426              -          \n Cost of share options and warrants awarded  -                         -              8,996                 -                  8,996      \n Loss for the year                           -                         -              -                     (98,910)           (98,910)   \n                                             _________                 _________      _________             _________          _________  \n At 30 April 2025                            211,273                   3,213,395      15,159                (3,082,355)        357,472    \n Share Issue                                 16,584                    46,239         -                     -                  -          \n Transfer of reserves                        -                         55,083         -                     (55,083)           -          \n Profit for the year                         -                         -              -                     65,999             65,999     \n                                             _________                 _________      ________              _________          _________  \n At 30 April 2026                            227,857                   3,314,717      15,159                (3,071,439)        486,294    \n                                             =========                 =========      =========             =========          =========  \n\nTransfer from retained earnings to share premium was made in relation to the\ngain recognised from the waiver of loans to comply with the requirements of UK\nlaw.\n\nSTATEMENT OF CASH FLOWS\n\nYear ended 30 April 2026\n\n                                                           Group 2026    Group 2025  \n                                                           £             £           \n Cash flow from operating activities                       (476,186)     247,071     \n Interest paid                                             (40,215)      (48,525)    \n Sundry income                                             2,747         1,898       \n Loss on Foreign Exchange                                  (13,097)      -           \n R&D tax credit received                                   142,791       195,798     \n                                                           _________     _________   \n Net cash flow from operating activities                   (383,960)     396,242     \n                                                           _________     _________   \n                                                                                     \n Financing Activities                                                                \n Repayment of long term loans                              (61,387)      (103,431)   \n Receipt of loan                                           100,000       -           \n Advances from directors and senior staff                  -             46,134      \n                                                           _________     _________   \n                                                           38,613        (57,297)    \n                                                           _________     _________   \n                                                                                     \n Net increase / (decrease) in cash and cash equivalents    (345,347)     338,945     \n Cash and Cash equivalents at 30 April 2025                428,957       90,012      \n                                                           _________     _________   \n Cash and Cash equivalents at 30 April 2026                83,610        428,957     \n                                                           =========     =========   \n Cash and Cash equivalents consists of:                                              \n Cash at bank and in hand                                  83,610        428,957     \n                                                           =========     =========   \n                                                                                     \n                                                                                     \n\n\n\n Net Debt Reconciliation  Current Debt  Non Current Debt  Cash       Total      \n                          £             £                 £          £          \n At 30 April 2024         (286,629)     (345,455)         90,012     (542,072)  \n Non - Cash Flow          -             60,102            -          60,102     \n Cash Flow                209,489       -                 338,945    548,434    \n                          ________      ________          ________   ________   \n At 30 April 2025         (77,140)      (285,353)         428,957    66,464     \n Non – cash flow          -             80,663            -          80,663     \n Cash Flow                              (38,613)          (345,347)  (383,960)  \n                          _________     _________         ________   _________  \n At 30 April 2026         (77,140)      (243,303)         83,610     (236,833)  \n                          =========     =========         =========  =========  \n\nNOTES TO THE FINANCIAL STATEMENTS\n\nYear ended 30 April 2026\n\nSummary of significant accounting policies\n\n(a)   General information and basis of preparation.\n\nDXS International PLC is a public company limited by shares incorporated in\nEngland and Wales. The address of the registered office is given in the\ncompany information on Page 1 of these financial statements.\n\nThe group's principal activities during the year were the development and\ndistribution of clinical decision support to General Practitioners, Nurses and\nRetail Pharmacies in the United Kingdom. The commercial side includes the\nlicensing of DXS products to various ICB's (Integrated Care Boards), the sale\nof e- detailing opportunities to the pharmaceutical industry, the UK Primary\nCare sector and the licencing of DXS technology to healthcare publishers.\n\nThe financial statements have been prepared in accordance with applicable\naccounting standards including Financial Reporting Standard 102, the Financial\nReporting Standard applicable in the UK and Republic of Ireland (FRS102) and\nthe Companies Act 2006.\n\nThe financial statements have been prepared on a going concern basis under the\nhistorical cost convention. The financial statements are prepared in sterling\nwhich is the functional currency of the company.\n\nIn the opinion of the Directors the group has sufficient funding to continue\nas a going concern for at least twelve months from the date of approval of the\nfinancial statements.\n\nThe significant accounting policies applied in the preparation of these\nfinancial statements are set out below. These policies have been consistently\napplied to all years presented unless otherwise stated.\n\n(b )   Intangible assets\n\nIntangible assets acquired separately from a business are capitalised at cost.\n\nResearch and development expenditure, other than specific identifiable\ndevelopment expenditure, is written off against profits in the year in which\nit is incurred.\n\nIdentifiable development expenditure is capitalised to the extent that the\ntechnical, commercial and financial feasibility can be demonstrated. Developed\nproducts are for use within the NHS and other medical institutions within both\nthe UK and internationally. The Group is already a supplier of services to the\nNHS.\n\nIntangible assets are amortised over a straight line basis over their useful\nlives. The useful lives of intangible assets are as follows:\n\n Intangible type          Useful life Reasons                                                            Reasons                                     \n Development expenditure  5 years from the date that the specific product is available for distribution  Period of time for benefit to be received.  \n\nProvision was made for impairment in 2024 as the recoverable amount of the\nasset was less than its carrying amount based on Directors judgement of the\nfuture revenue to be derived from each product. The Directors have considered\nthe current value of the asset and believe that no additional impairment\ncharge is required in the current year. (Note 1(m))\n\n(c ) Tangible fixed assets\n\nThe company capitalises items purchased as Tangible Fixed Assets which have a\ncost in excess of £550.\n\nTangible fixed assets are stated at cost less accumulated depreciation.\n\nDepreciation is provided on all tangible fixed assets at rates calculated to\nwrite off the cost , less estimated residual value, of each asset on a\nsystematic basis over its expected useful life as follows:\n\n Office equipment  3-4 years straight line.  \n\n(d)   Debtors and creditors receivable/ payable within one year\n\nDebtors and creditors with no stated interest rate and receivable or payable\nwithin one year are recorded at transaction price. Any losses arising from\nimpairment are recognised in the profit and loss account in other\nadministration expenses.\n\n(e)   Loans and borrowings\n\nLoans and borrowings are initially recognised at the transaction price\nincluding transaction costs. Subsequently they are measured at amortised cost\nusing an effective interest rate method. If an arrangement constitutes a\nfinance transaction it is measured at present value.\n\n(f)   Grants\n\nGovernment Grants, including non - monetary grants, shall not be recognised\nuntil there is reasonable assurance that :\n\n      (a)   the entity will comply with the conditions attached to\nthem; and\n\n      (b)   the grants will be received.\n\nAn entity shall recognise grants either based on the performance model or the\naccrual model. In the current year and prior year, the Grant has been\naccounted for on the accrual basis over the period in which the Group\nrecognised the related costs for which the grant is intended to compensate.\n\n(g)   Tax\n\nCurrent tax represents the amount of tax payable or receivable in respect of\nthe taxable profit for the current or past reporting periods. It is measured\nat the amount expected to be paid or recovered using the tax rates and laws\nthat have been enacted or substantively enacted by the reporting date.\n\n(h)   Turnover and other income\n\nTurnover is measured at the fair value of the consideration received or\nreceivable net of VAT and trade discounts. The policy adopted for the\nrecognition of turnover is as follows:\n\nSale of services and products\n\nTurnover is from the sale of products and services to the pharmaceutical\nindustry and the UK Primary Care sector and is recognised over the term of\nservice contract and is apportioned on a time basis representing the delivery\nof the service.\n\n(i)   Foreign currency\n\nForeign currency transactions are initially recognised by applying to the\nforeign currency amount the exchange rate between the functional currency and\nthe foreign currency at the date of the transaction.\n\nMonetary assets and liabilities denominated in a foreign currency at the\nbalance sheet date are translated using the closing rate.\n\nForeign exchange gains or losses are recognised in the Income Statement.\n\n(j)   Employee benefits\n\nWhen employees have rendered service to the company, short term employee\nbenefits to which the employees are entitled are recognised at the\nundiscounted amount expected to be paid in exchange for that service.\n\nThe company operates a defined contribution plan for the benefit of its\nemployees. Contributions are expensed as they become payable.\n\n(k)   Leases\n\nRentals payable under operating leases are charged to the income statement on\na straight line basis over the period of the lease.\n\n(l) Share option policy\n\nThe company recognised as an expense, the fair value of share options granted\nover their vesting period. The fair value is calculated by applying an option\npricing model.\n\n(m)   Key judgements and Key accounting estimates\n\nThe Key judgements or Key Accounting estimates with a material effect on the\ncarrying value of assets and liabilities are set out below -.\n\nGoing concern\n\nIn regards to the going concern of the group, the directors have considered\ncash flow forecasts for the period to April 2028 which include estimates to be\nearned from the new Next Gen SMART Referral solution which is anticipated to\nbe available for distribution during early 2027. Indications are that there\nwill be a significant demand for this product. Existing Point of Care\ncustomers have all renewed their continuity contracts until September 2027.\nAlso included within the Budget is a CPI price increase in April 2027 and a\nlong overdue product price increase in October 2027. The renewal of the NHS\ncentral funding framework which is expected to become effective in October\n2027 will enable existing NHS customers to procure the DXS SMART Referral\nsolution for practices that as yet do not have the referral solution\n\nThe Expertcare solution has been selected, provisionally, for inclusion in a\nmajor project by the NHS commencing in early 2027.\n\nThe successful evaluations of both the SMART Referral and Expertcare\nsolutions, both demonstrating strong ROI for the NHS, bode well for procuring\nnew sales for these solutions for 2027/28.\n\nThe Pharma division has found a number of new customers since the year end. A\nprice increase has also been implemented in the current year, which has been\naccepted by the current customers. The indication is that, with the benefit of\nthe new products, this division will be expanding in the forthcoming year.\n\nAlso included are costs which, if forecasted sales are slower than\nanticipated, can be reduced accordingly. While the forecasts include a number\nof positive assumptions relating to new customer acquisitions, anticipated\nsales from recently developed products, future contract opportunities, planned\nprice increases and potential cost mitigation actions, these represent\nmanagements best estimates rather than assumptions fundamental to the going\nconcern assessment. Sensitivity analysis performed demonstrates that, even if\nthese forecast benefits are excluded in full, the Group continues to maintain\nadequate liquidity and headroom throughout the forecast period and remains\nable to meet its liabilities as they fall due. Accordingly, the directors'\nconclusion that the Group is a going concern is not dependent upon the\nsuccessful delivery of these initiatives, and no material uncertainty relating\nto going concern has been identified.\n\nBased on the foregoing, the directors consider it appropriate to adopt the\ngoing concern basis of accounting and are satisfied that there is no material\nuncertainty.\n\nResearch and Development Tax credit\n\nThe Research and Development tax credit received from HMRC is not a Government\ngrant but a recognition of the costs incurred in respect of the company's\nresearch and development and is received through an adjustment to the taxable\nincome of the company.\n\nImpairment\n\nAs per the NHS mandate requiring NHS accredited suppliers to continue a\nprocess of innovation, the Group has invested heavily into developing new\ninnovative solutions to meet the NHS unmet needs. However, while there is no\ndoubt as to the potential benefits to be realised for the NHS, the slow pace\nat which the NHS has been, and continues to operate is frustrating.\n\nThe Government did not provide the anticipated funding to the NHS during\n2024/25 or 2025/26 . Funds were not available for purchase of new products by\nthe NHS, The Government has indicated that significant funds for new products\nwill be made available in the fiscal year commencing October 2027.\n\nThe slow pace at which the NHS has operated over the last few years has been\nextremely frustrating. The main reasons are the reduction in the ICBs causing\nstaff concerns for potential staff redundancies, the delayed appointment of\nsenior staff in the new combined organisations and the appointment of 2\nSecretaries for State since the last General election.\n\nThere are indications that the NHS is slowly improving its delivery time for\npatients and is taking steps to resolve the current issues within product\nprocurement.\n\nThe company's products are in line with the those included in the NHS new 10\nyear plan. The new products are undergoing pilot testings. The initial reports\nindicate that only minor amendments to the products are required. And there\nappears a demand for these products when they have completed all the tests.\nThere are also studies showing a significant cash saving to the NHS by the\nutilisation of these products\n\nGiven all these factors, the Directors believe that there are no impairment\nindicators and no further impairment provision is required in the current\nyear.\n\n(n)   Reduced disclosure\n\nDXS International PLC meets the definition of a qualifying entity under FRS\n102 paragraph 1.12(b) and has therefore taken advantage of the disclosure\nexemption in relation to the parent cash flow statement.\n\nAttachment\n*     DXS - Announcement Full Year 2026 - 22 September 2026\n(https://ml-eu.globenewswire.com/Resource/Download/c6e565f3-08b7-49d8-885c-22f0f1fc9d44)"},"type":"article","timestamp":"2026-09-22T06:00:00.55569437Z","server_sent_at_ms":1790056800555},"received_at":"2026-09-22T06:00:03.080Z","source_url":null},"analysis":{"id":"137659","press_release_id":"149078","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":["Revenue declined 5.2% year-over-year to £3,289,052","Profit of £61,839 driven mainly by cost cuts and the R&D tax credit; underlying operating loss of £58,484","Cash at bank fell to £83,610 from £428,957, with net cash outflow of £345,347 and negative operating cash flow of £383,960","Growth plan contingent on new NHS central funding framework expected October 2027; upsell timing and quantum not guaranteed","Cyber security incident affecting office servers reported 18 December 2025 (company states it was swiftly contained)","No dividend recommended"],"eventType":"earnings","narrative":"DXS International returned to profitability in FY2026, posting a profit of £61,839 against a £94,750 loss the prior year, while revenue slipped 5.2% to £3,289,052.\n\nThe swing was driven mainly by cost discipline and an R&D tax credit rather than operations, with the group still recording an operating loss of £58,484, and cash at bank fell to £83,610 from £428,957.\n\nAll customers renewed contracts for a further 18 months, and NHS Integrated Care Board consolidation from 42 to 28 is expected to bring GP practices covering roughly 6-8 million additional patients into reach — an upsell that could add more than £1 million of annual recurring revenue from January 2027, dependent on the new NHS framework.","sentiment":"mixed","agentHooks":{"shouldPost":false,"suggestedAngle":"NHS-focused digital health micro-cap swings to full-year profit and locks in 18-month renewals, but revenue fell 5.2% and cash at bank dropped to £84k — the ICB-consolidation upsell into 2027 is the watch item."},"keyFigures":{"eps":"0.1p","revenue":3289052,"guidance":"Price increase planned between April and October 2027; first ICB-consolidation upsell opportunities expected from January 2027; if 50% of consolidated-practice customers standardise on DXS SMART Referrals this could generate more than £1 million of additional annual recurring revenue, dependent on the new NHS framework expected October 2027.","customDimensions":{"currency":"GBP","net_profit_gbp":61839,"tax_credit_gbp":157791,"cash_at_bank_gbp":83610,"gross_profit_gbp":2860843,"rd_investment_gbp":713472,"available_cash_gbp":393258,"dividend_recommended":false,"contract_renewal_term":"18 months","arr_upsell_opportunity_gbp":1000000,"additional_patients_addressable":"6-8 million"}},"quotedText":"After several challenging years, we believe DXS is increasingly well\npositioned to benefit from the opportunities emerging across the NHS.","namedEntities":{"people":[{"name":"David Immelman","role":"CEO"},{"name":"Bob Sutcliffe","role":"Chairman"},{"name":"Steven Bauer","role":"COO"},{"name":"Claire Louise Noyce","role":"Contact at Hybridan LLP, AQSE Corporate Broker and Corporate Advisor"}],"products":["SMART Referrals","NexGen SMART Referrals","ExpertCare","Managed Services","DXS Hubs","Metadata","SMART Forms","Lipids solution","CVD prevention solution"],"companies":[{"name":"DXS International plc","ticker":"DXSP","relationship":"filer"},{"name":"NHS","relationship":"primary customer and end-market (ICBs licensing DXS clinical decision support)"},{"name":"Hybridan LLP","relationship":"corporate broker and corporate advisor"}],"dollarAmounts":[{"amount":"£3,289,052","context":"FY2026 revenue (2025: £3,469,917)"},{"amount":"£61,839","context":"profit for the year ended 30 April 2026"},{"amount":"£94,750","context":"prior-year (FY2025) loss"},{"amount":"£393,258","context":"period-end available cash including £309,648 of unutilised debtor drawdowns"},{"amount":"£83,610","context":"cash at bank and in hand at 30 April 2026"},{"amount":"£1 million","context":"estimated additional annual recurring revenue if 50% of ICB-consolidated practices standardise on DXS SMART Referrals"},{"amount":"£713,472","context":"R&D investment during the financial year"},{"amount":"£100,000","context":"additional loan drawn during the year (balance £89,964 at April 2026)"}]},"materialImpact":{"score":3,"reasoning":"Full-year audited results show a swing to profit (£61,839 vs a £94,750 loss) with all customers renewing for a further 18 months, but revenue fell 5.2%, the operating result remained a loss propped up by the R&D tax credit, and cash at bank dropped to £83,610 from £428,957."},"tickerRelevance":{"others":[],"primary":"DXSP"},"globalImportance":14,"audienceRelevance":8,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap (AQSE Growth Market)","eventGravity":"annual results — swing to net profit on a 5.2% revenue decline","sectorWeight":"health care technology / clinical decision support","issuerAuthored":true,"geographicMarket":"UK","liquidityConsideration":"cash at bank down to £83,610; going concern stated with no material uncertainty"}},"event_type":"earnings","event_type_secondary":["operations_update"],"sentiment":"mixed","material_impact_score":3,"narrative":"DXS International returned to profitability in FY2026, posting a profit of £61,839 against a £94,750 loss the prior year, while revenue slipped 5.2% to £3,289,052.\n\nThe swing was driven mainly by cost discipline and an R&D tax credit rather than operations, with the group still recording an operating loss of £58,484, and cash at bank fell to £83,610 from £428,957.\n\nAll customers renewed contracts for a further 18 months, and NHS Integrated Care Board consolidation from 42 to 28 is expected to bring GP practices covering roughly 6-8 million additional patients into reach — an upsell that could add more than £1 million of annual recurring revenue from January 2027, dependent on the new NHS framework.","key_figures":{"eps":"0.1p","revenue":3289052,"guidance":"Price increase planned between April and October 2027; first ICB-consolidation upsell opportunities expected from January 2027; if 50% of consolidated-practice customers standardise on DXS SMART Referrals this could generate more than £1 million of additional annual recurring revenue, dependent on the new NHS framework expected October 2027.","customDimensions":{"currency":"GBP","net_profit_gbp":61839,"tax_credit_gbp":157791,"cash_at_bank_gbp":83610,"gross_profit_gbp":2860843,"rd_investment_gbp":713472,"available_cash_gbp":393258,"dividend_recommended":false,"contract_renewal_term":"18 months","arr_upsell_opportunity_gbp":1000000,"additional_patients_addressable":"6-8 million"}},"named_entities":{"people":[{"name":"David Immelman","role":"CEO"},{"name":"Bob Sutcliffe","role":"Chairman"},{"name":"Steven Bauer","role":"COO"},{"name":"Claire Louise Noyce","role":"Contact at Hybridan LLP, AQSE Corporate Broker and Corporate Advisor"}],"products":["SMART Referrals","NexGen SMART Referrals","ExpertCare","Managed Services","DXS Hubs","Metadata","SMART Forms","Lipids solution","CVD prevention solution"],"companies":[{"name":"DXS International plc","ticker":"DXSP","relationship":"filer"},{"name":"NHS","relationship":"primary customer and end-market (ICBs licensing DXS clinical decision support)"},{"name":"Hybridan LLP","relationship":"corporate broker and corporate advisor"}],"dollarAmounts":[{"amount":"£3,289,052","context":"FY2026 revenue (2025: £3,469,917)"},{"amount":"£61,839","context":"profit for the year ended 30 April 2026"},{"amount":"£94,750","context":"prior-year (FY2025) loss"},{"amount":"£393,258","context":"period-end available cash including £309,648 of unutilised debtor drawdowns"},{"amount":"£83,610","context":"cash at bank and in hand at 30 April 2026"},{"amount":"£1 million","context":"estimated additional annual recurring revenue if 50% of ICB-consolidated practices standardise on DXS SMART Referrals"},{"amount":"£713,472","context":"R&D investment during the financial year"},{"amount":"£100,000","context":"additional loan drawn during the year (balance £89,964 at April 2026)"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-22T06:28:32.012Z","global_importance":14,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap (AQSE Growth Market)","eventGravity":"annual results — swing to net profit on a 5.2% revenue decline","sectorWeight":"health care technology / clinical decision support","issuerAuthored":true,"geographicMarket":"UK","liquidityConsideration":"cash at bank down to £83,610; going concern stated with no material uncertainty"}},"durationMs":195720,"modelName":"glm-5.3-flash"}}